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I N T R O D U C T I O N
Dilutionmethods are used to determine theminimum inhibi-
tory concentrations (MICs) of antimicrobial agents and are the
reference methods for antimicrobial susceptibility testing
against which other methods, such as disk di¡usion, are cali-
brated. MIC methods are widely used in the comparative test-
ing of new agents. In clinical laboratories they are used to
establish the susceptibility of organisms that give equivocal
results in disk tests, for tests on organisms where disk tests may
be unreliable, and when a more accurate result is required for
clinical management.
In dilution tests, microorganisms are tested for their ability
to produce visible growth on a series of agar plates (agar dilu-
tion) or in microplate wells of broth (broth microdilution)
containing dilutions of the antimicrobial agent. The lowest
concentration of an antimicrobial agent that will inhibit the
visible growth of amicroorganism is known as theMIC.
The agar dilution method described in this document is
based on that described in the report of an international colla-
borative study of antimicrobial susceptibility testing [1] and is
very similar to those described and recommended in many
countries, including France [2], Germany [3], Norway [4],
Sweden [5], theUK [6] and theUSA [7].
M E D I U M
Although several susceptibility testing media are available in
Europe, a clear choice for a reference medium remains to be
determined. Mueller^Hinton (MH) agar shows no perfor-
mance advantages over some other media but is probably the
most widely used medium internationally, and there is a USA
National Committee for Clinical Laboratory Standards
(NCCLS) document which describes procedures for evaluat-
ing MH agar [8]. MH agar which meets the requirements of
the NCCLS standard [8] is considered the referencemedium.
Supplements should not be used unless necessary for
growth of the organisms. Five per cent de¢brinated blood is
added for fastidious organisms such as streptococci andMorax-
ella catarrhalis. Several supplements for Haemophilus spp. and
Neisseria spp. have been suggested but evidence of perfor-
mance is needed. Five per cent de¢brinated bloodwith 20mg/
L NAD, 5% chocolated blood, and supplemented GC agar
have been suggested.
A N T I M I C R O B I A L A G E N T S
Obtain antimicrobial powders directly from the manufacturer
or from commercial sources.The agent must be supplied with
a stated potency (mgor InternationalUnits per g powder, or as
a percentage potency), an expiry date and details of recom-
mended storage conditions. Store powders in sealed contain-
ers in the dark at 4 C with a desiccant unless otherwise
recommended by the manufacturer. Ideally, hygroscopic
agents should be dispensed into aliquots, and one aliquot used
on each test occasion. Allow containers towarm to room tem-
perature before opening them to avoid condensation of water
on the powder.
Preparation of stock solutions
Use an analytical balance when weighing agents. Allowance
for the potency of the powder can be made by use of the fol-
lowing formula:
Weight of powder mg 
Volume of solvent mL  Concentration mg=L
Potency of powder mg=g
Alternatively, given a weighed amount of antimicrobial pow-
der, the volume of diluent needed may be calculated from the
formula:
Weight of solvent mL 
Weight of powder mg  Potency of powder mg=g
Concentration mg=L
Concentrations of stock solutions should be 1000mg/L or
greater, although the solubility of some agents will be limit-
ing. The actual concentrations of stock solutions will depend
on the method of preparing working solutions. Manufac-
turers' recommendations for solvents and diluents should be
followed, but where possible agents should be dissolved and
diluted in sterile distilled water. Some agents that require
alternative solvents are listed in Table1. Sterilization of solu-
tions is not usually necessary. If required, sterilization should
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be by membrane ¢ltration, and samples before and after steri-
lization must be compared by assay to ensure that adsorption
to the membrane has not occurred. Unless otherwise
instructed by the manufacturer, store stock solutions frozen in
aliquots at ÿ20 C or below. Most agents will keep at ÿ60 C
for at least 6 months. Stock solutions must be frozen as soon as
possible after preparation, used promptly on defrosting and
not re-frozen.
Preparation of working solutions
The range of concentrations tested will depend on the organ-
isms and antimicrobial agent being tested, but a two-fold
dilution series based on 1mg/L is conventionally used.
Twenty-milliliter volumes of agar are commonly used in 9-
cm Petri dishes for agar dilution MICs. Two alternative dilu-
tion schemes are given inTables 3 and 4. Both schemes involve
adding 19-mL volumes of molten agar to 1-mL volumes of
antimicrobial solution. The more conventional method is
based on diluting a 10 240mg/L stock solution, always mea-
suring 1-mL volumes of antimicrobial solution (Table 2). The
other method (Table 3) is based on diluting a 10 000mg/L
stock solution and involves measuring various volumes of
antimicrobial solution by the use of high-precision variable-
volume micropipettes, which are now widely available. An
alternative to the method in Table 3 is to omit the distilled
water added to make antimicrobial volumes up to 1mL and
instead to add a variable volume of molten agar to make the
total volume 20mL.
P R E P A R A TI O N O F P LA T E S
Prepare agar as recommended by the manufacturer. Allow
the sterilized agar to cool to 50 C in a water-bath. Prepare a
dilution series of antimicrobial agents, as above, in 25^30-mL
containers. Include a drug-free control. Add 19mL of molten
agar to each container, mix thoroughly, and pour the agar into
prelabeled sterile Petri dishes on a level surface. Allow the
plates to set at room temperature and dry the plates so that no
drops of moisture remain on the surface of the agar. Do not
overdry plates.
Plates should not be stored unless the agents have been
shown to be stable on storage. Clavulanic acid and carbape-
nems are particularly unstable.
Table1 Solvents and diluents for antimicrobial agents requiring solvents other than water
Antimicrobial agent Solvent Diluent
Amoxycillin Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Ampicillin Phosphate buffer 0.1 M, pH 8.0 Phosphate buffer 0.1 M, pH 6.0
Azithromycin Ethanol 95% Water
Aztreonam Saturated sodium bicarbonate solution Water
Ceftazidime Saturated sodium bicarbonate solution Water
Chloramphenicol Ethanol 95% Water
Clavulanic acid Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Erythromycin Ethanol 95% Water
Fluoroquinolones Half volume water,
a minimum volume of 0.1 M NaOH to dissolve,
then make up to total volume with water
Water
Fusidic acid Ethanol 95% Water
Imipenem Phosphate buffer 0.01 M, pH 7.2 Phosphate buffer 0.01 M, pH 7.2
Mezlocillin Methanol Water
Meropenem Phosphate buffer 0.01 M, pH 7.2 Phosphate buffer 0.01 M, pH 7.2
Nalidixic acid Half volume water,
a minimum volume of 0.1 M NaOH to dissolve,
then make up to total volume with water
Water
Nitrofurantoin Dimethylformamide Phosphate buffer 0.1 M, pH 8.0
Rifampicin Methanol Water
Sulbactam Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Sulfonamides Half volume water,
a minimum volume of 0.1 M NaOH to dissolve,
then make up to total volume with water
Water
Ticarcillin Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Trimethoprim Half volume water,
a minimum volume of 0.1 M lactic acid or 0.1 M HCl to dissolve,
then make up to total volume with water
Water
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Table 2 Preparation of dilutions of agents for use in agar dilution susceptibility tests
Antimicrobial
concentration (mg/L)
in stock solution
Volume stock
solution (mL)
Volume
distilled water (mL)
Antimicrobial
concentration
obtained (mg/L)
Final concentration in
medium after addition
of 19 mL of agar
10 240 1 0 10 240 512
10 240 1 1 5120 256
10 240 1 3 2560 128
2560 1 1 1280 64
2560 1 3 640 32
2560 1 7 320 16
320 1 1 160 8
320 1 3 80 4
320 1 7 40 2
40 1 1 20 1
40 1 3 10 0.5
40 1 7 5 0.25
5 1 1 2.5 0.125
5 1 3 1.25 0.06
5 1 7 0.625 0.03
0.625 1 1 0.3125 0.015
0.625 1 3 0.1562 0.008
0.625 1 7 0.0781 0.004
Table 3 Alternative method of preparation of dilutions of antimicrobial agents for use in agar dilution susceptibility tests
Antimicrobial
concentration
(mg/L) in stock
Volume stock
solution (mL)
Volume distilled
water (mL)
Antimicrobial
concentration
obtained (mg/L)
Final concentration in
medium after addition
of 19 mL of agar
10 000 1 9 1000 ±
10 000 0.1 9.9 100 ±
100 1 9 10 ±
100 0.1 9.9 1 ±
10 000 1.024 0 10 240 512
10 000 0.512 0.488 5120 256
10 000 0.256 0.744 2560 128
10 000 0.128 0.872 1280 64
1000 0.64 0.36 640 32
1000 0.32 0.68 320 16
1000 0.16 0.84 160 8
100 0.8 0.2 80 4
100 0.4 0.6 40 2
100 0.2 0.8 20 1
10 1 0 10 0.5
10 0.5 0.5 5 0.25
10 0.25 0.75 2.5 0.125
10 0.125 0.875 1.25 0.06
1 0.625 0.375 0.625 0.03
1 0.313 0.687 0.3125 0.015
1 0.156 0.844 0.1562 0.008
1 0.078 0.922 0.0781 0.004
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P R EP A R A T IO N O F I N O C U LU M
Standardize the density of inoculum to give 104 colony-form-
ing units (CFU) per spot on the agar. Use four or ¢ve colonies
of a pure culture to avoid selecting an atypical variant. The
inoculum may be prepared by emulsifying overnight colonies
from an agar mediumor bydiluting a broth culture.The broth
usedmust not be antagonistic to the agent tested. A 0.5McFar-
land standard may be used for visual comparison to adjust the
suspension to a density equivalent to approximately 108 CFU/
mL. Alternatively, inocula can be adjusted photometrically.
Dilute the suspensions of organisms in 0.85% saline or broth
to give 107 CFU/mL. Plates must be inoculated within 30min
of standardizing the inoculum, to avoid changes in inoculum
density.
IN O C U L A T IO N O F P L A T ES
Mark the plates so that the orientation is obvious. Transfer
diluted bacterial suspensions to the wells of an inoculum-
replicating apparatus. Use the apparatus to transfer the inocula
to the series of agar plates, including a control plate without
antimicrobial agent. Replicator pins 2.5mm in diameter will
transfer about1 mL, i.e. an inoculumof104 CFU/spot. Alterna-
tively, a micropipette or standard loop may be used to inocu-
late plates. Allow the inoculum spots to dry at room
temperature before inverting the plates for incubation.
IN C U B A TI O N O F P L A T ES
Incubate plates at 35^37 C in air for 18 h. In order to avoid
uneven heating, do not stack plates more than ¢ve high. If the
incubation period is extended for slow-growing organisms,
the stability of the agent over the incubation period must be
assessed by the inclusion of control strains with knownMICs.
Avoid incubation in an atmosphere containing 5%CO2 unless
necessary for growth of the organisms (e.g. Neisseria spp.).
Incubate methicillin/oxacillin susceptibility tests on staphylo-
cocci at 30 C.
R EA D IN G R ES U L T S
TheMIC is the lowest concentration of the agent that comple-
tely inhibits visible growth as judged by the naked eye, disre-
garding a single colony or a thin haze within the area of the
inoculated spot. A trailing endpoint with a small number of
colonies growing on concentrations several dilutions above
that which inhibits most organisms should be investigated by
subculture and retesting. Such trailing endpoints may indicate
contamination, resistant variants, b-lactamase-producing
organisms, or, if incubation is prolonged, regrowth of suscep-
tible organisms following deterioration of the agent. With
sulfonamides and trimethoprim, endpoints may be seen as a
reduction in growth, and a haze of growth may be seen at sev-
eral dilutions above the actualMIC.
F A S T ID I O U S O R G A N IS MS
Testing of fastidious organisms may require supplementation
of the medium, enrichment of the incubation atmosphere
with 5% CO2, or extension of the incubation time.The e¡ect
of any alterations in test conditions must be assessed by the
inclusion of appropriate control organisms.
M E TH IC IL L IN / O X A C IL L I N S U S C E P TI B IL IT Y T ES T S
O N S T A P H Y LO C O C C I
A combination of test conditions a¡ects the expression of
intrinsic resistance to b-lactam agents in staphylococci. The
following apply to tests with staphylococci and all b-lactam
agents:
1. Add 2%NaCl to themedium.
2. Incubate tests at 30 C (note that some coagulase-negative
strains do not grow well at 30 C and may require incubation
for 48 h).
3. Incubate tests for 24 h. Continue incubation for a further
24 h for coagulase-negative staphylococci.
Penicillinase hyperproducing strains of Staphylococcus aureus
may have methicillin/oxacillin MICs raised by one or two
two-fold dilution steps compared with other penicillinase-
producing strains.
T E S TS O N b-L A C T A M A SE - P R O D U C IN G
O RG A N IS M S
When testing organisms that produce extracellular b-lacta-
mases, the MICs of penicillins and cephalosporins may be
markedly a¡ected by the density of inoculum. The standard
inoculum may result in MICs only slightly higher than those
obtained with susceptible strains. b-Lactamase production can
be more reliably detected in staphylococci, gonococci,Haemo-
philus in£uenzae andMoraxella catarrhalis by de¢nitive tests such
as nitroce¢n-based techniques. Among Gram-negative
organisms, the e¡ect of the inoculum depends on the amount
of enzyme produced, and the activity of the enzyme against
the particular penicillin or cephalosporin under test. E¡ective
standardization of the inoculum is necessary to avoid large
variations inMIC results.
Q U A L IT Y C O N T RO L
Routine quality control is achieved by the use of control
strains, e.g. as shown in Table 4.Working cultures of control
strains may be stored on digest agar slopes and subcultured
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weekly.Working cultures should be replaced monthly from
lyophilized or frozen cultures (atÿ60 C or below).
Test colonies of control cultures as recommended for test
cultures. Include control cultures with each batch of tests, and
test new lots of agar before they are used routinely. In general,
MICs of control organisms should be within one two-fold
dilution step of the target values given in Table 4. As well as
target values for tests on the reference medium, MH agar, tar-
get values for control strains tested on Iso-Sensitest agar are
included for comparison. In addition:
1. The control plate without antimicrobial agents must show
adequate growth of both test and control strains.
2. Plate a sample of inoculum prepared for each strain on a
suitable agarmedium to ensure that the inoculum is a pure cul-
ture.
3. Occasionally check that the method of producing the cor-
rect inoculum density is working by counting the number of
organisms in the inocula.
4. Check that endpoints are read consistently by all sta¡ inde-
pendently reading a selection of tests.
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